Revenue Breakdown
Composition ()
No data
Revenue Streams
Aytu Biopharma Inc (AYTU) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is ADHD portfolio, accounting for 94.7% of total sales, equivalent to $13.16M. Other significant revenue streams include Pediatric portfolio and Other . Understanding this composition is critical for investors evaluating how AYTU navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Aytu Biopharma Inc maintains a gross margin of 62.95%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -10.83%, while the net margin is 14.15%. These profitability ratios, combined with a Return on Equity (ROE) of -50.23%, provide a clear picture of how effectively AYTU converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, AYTU competes directly with industry leaders such as DARE and PTN. With a market capitalization of $25.57M, it holds a significant position in the sector. When comparing efficiency, AYTU's gross margin of 62.95% stands against DARE's 100.00% and PTN's 100.00%. Such benchmarking helps identify whether Aytu Biopharma Inc is trading at a premium or discount relative to its financial performance.
